Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Caffeine on Cognition in Schizophrenia
NCT02832401Completed
- Sponsor
- Nova Scotia Health
- Start
- Sep 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia comparing Caffeine with Placebo (2 arms). Primary endpoints: Event-related potential amplitudes and Event-related potential latencies. Started Sep 2016; status: completed.
02
Drugs
caffeine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02832401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832401.